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INTRODUCTION 
Despite the variety of antiepileptic medications currently 
marketed in the United States, approximately one-fifth of patients 
fail to experience adequate seizure control1 and others do so only at 
the expense of toxic side effects. Thus a need for new antiepileptic 
drugs with greater efficacy and less toxicity remains. 
BWA78U is a structurally unique antiepileptic compound developed 
in the Wellcome Research Laboratories. It is a purine structurally 
related to the methylxanthines and designated by the chemical name 
9- [2-fluorobenzyl]-6-methylamino-9H-purine mono-hydrochloride. 
Pharmacological studies in animals have shown BWA78U to protect 
rats against maximal electroshock (MES) [ED^ 2.5i0.4 mg/kg, orally] 
and 3-mercaptoproprionic acid [ED^^ 16±2 mg/kg, intraperitoneally] 
induced seizures. Mice were also protected against maximal electro-
shock-induced seizures [ED^ ^ 14±2 mg/kg, orally] and audiogenic 
seizures [ED^ 3.7±0.3 mg/kg, intraperitoneally]. Neither species 
2 
was protected against metrazol or picrotoxin induced seizures. When 
compared with known antiepileptic agents, this pattern of protection 
against experimentally induced seizures would predict effectiveness 
in focal partial seizures, generalized seizures with a focal origin 
2 3 
and bilateral generalized seizures. ' 
When compared with diphenylhydantion and phenobarbital sodium 
against maximal electroshock-induced seizures in rats, BWA78U was 
found to be six and eight times more potent, respectively. In the 
mouse, BWA78U was equipotent with phenobarbital sodium and one and 
one-half times more potent than diphenylhydantoin against MES induced 
2 
seizures. From these data, the projected antiepileptic dose in man 
2 
would be 0.5 to 1.0 mg/kg, orally. 
Pharmacokinetic studies in rats demonstrated that BWA78U is 
rapidly absorbed after a single oral dose, with a peak plasma concen-
tration occurring at approximately one hour. However, it appears to 
undergo substantial first-pass metabolism to the N-demethylated form, 
BWA352U. Duration of action when given by the oral route to rats and 
mice was approximately five hours. The beta elimination half-life 
appears to be dose dependant. 
Adverse effects in acute toxicity studies in rats and mice 
included ataxia, decreased activity and seizures at doses 10 to 25 
times those controlling experimentally induced seizures. Chronic 
oral dosing studies showed no drug-related changes at 5 mg/kg/day or 
10 mg/kg/day when given for 90 days to rats. Increased salivation 
and slight decreases in food consumption were the only changes seen 
at 20 mg/kg/day. Higher doses of 60 mg/kg/day and 180 mg/kg/day were 
associated with ataxia, decreased activity and slight increases in 
serum glucose.^ 
Adverse effects were not observed, with the exception of ernesis 
and soft mucoid or watery feces in dogs at 20 mg/kg/day. At doses of 
40 mg/kg/day given for 90 days, body tremors, ataxia and seizure 
activity were seen in two of eight dogs. Animals in all dosage 
ranges as well as those in the placebo group experienced slight 
spontaneous retinal atrophy; however, this effect was more pronounced 
2 
in the higher dosage ranges. 
These preliminary studies in animals indicated that BWA78U may 
be an effective anticonvulsant agent especially for use in focal 
seizures, generalized seizures with a focal origin and bilateral 
generalized seizures. The objective of this phase I clinical drug 
trial was to evaluate the tolerance of increasing single oral doses 
of BWA78U in human volunteers. Serum drug concentrations were also 
determined in order to begin to characterize the pharmacokinetic 
parameters of this compound in humans. 
METHODS 
The study protocol was approved by the Institutional Review 
Board of the University of Utah, Each subject gave written informed 
consent prior to enrollment in the study (Appendix I), 
Subjects. Fourteen healthy male volunteers were recruited to 
participate in the study (including two alternates). Only those 
volunteers meeting all admission criteria were entered into the study 
(Appendix II). 
Study Design. In this parallel, double-blind trial, 12 subjects 
were assigned to one of two dosing groups and randomized to receive 
either escalating doses of BWA78U (25,50,100,150 and 300 mg) or 
placebo (Table 1). Two alternates were utilized to replace subjects 
number 2 and 5 (see results section). 
The study was conducted in three phases: 1) a screening phase, 
2) a treatment phase with five planned drug administrations at seven 
day intervals and 3) a follow-up phase. Subjects in Group I under-
went each dosing one week prior to subjects in Group II. This 
staggering of dosing allowed for assessment of safety prior to 
exposing all subjects to the drug at each dose (Table 2). 
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Screening Phase. Seven to 21 days prior to the first dosing 
period for each subject, the screening phase was conducted, A 
medical and medication, history were taken to assure that each subject 
met the admission criteria. Blood and urine samples were obtained 
for baseline laboratory tests including; complete blood count (CBC) 
with differential, serum chemistries (SMA 20) and urinalysis. In 
addition each subject underwent a physical examination, vital sign 
determination (oral temperature, respiratory rate, supine and stand-
ing pulse and blood pressure), standard 12-lead electrocardiogram, 
neurological examination, ophthalmological examination (including 
slit-lamp) and urine drug screen. Only those subjects with screening 
results within a clinically acceptable range were admitted to the 
study. 
At this time each volunteer was asked to complete an 18 item 
visual analog scale (Appendix III). The visual analog scale is a 
tool which has been tested for its ability to detect central nervous 
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system effects of various medications. The scale consists of 18 
sets of antonyms joined by a 10 millimeter line. Subjects were asked 
to rate where on the line they felt they were at the time of the 
assessment. The point at which the mark crossed the line was 
measured in millimeters as a means of quantifying the responses. 
Treatment Phase. Subjects were admitted to the Drug Research 
Center from 12 to 24 hours prior to each dosage administration. Upon 
admission, volunteers received physical and neurological examinations 
and vital signs were determined. In addition, urine for a drug 
screen was collected. Only those subjects with acceptable test 
results were administered the drug. Subjects were instructed to eat 
nothing and drink only water from the evening prior to dosing until 
four hours following each dose. 
Each dose of drug and placebo was administered as six identical 
capsules. A combination of capsules containing 25 mg or 50 mg of 
BWA78U HC1 or placebo were used to attain the proper dosage (0 mg, 25 
mg, 50 mg, 100 mg 150 mg of BWA78U). The capsules were administered 
along with 200 milliliters of water. Within the hour prior to 
dosing, a 12-lead electrocardiogram was done on each subject, vital 
signs were taken, a visual analog scale and probe for adverse 
experiences administered. Blood and urine were collected for base-
line laboratory value determination. Immediately prior to dosing, an 
additional blood sample was obtained for determination of amylase and 
lipase levels and as a baseline for plasma drug levels. 
Volunteers remained in the Drug Research Center for 48 hours 
following each dose. Subjects were requested not to discuss any 
effects they experienced among themselves. Periodic clinical assess-
ments were made during the dosing period as outlined in Table 3. 
In addition, urine was collected in two alllquots from 0 to 24 
hours and from 24 to 48 hours post dose for analysis of BWA78U and 
its major metabolite BWA352U. Blood for determination of BWA78U and 
BWA352U plasma concentrations was drawn at the times indicated in 
® 
Table 3. A lavender stoppered #6451 Vacutainer (Becton Dickson, 
Rutherford, New Jersey) was utilized. Samples were kept on ice and 
centrifuged within one hour of the blood draw. Plasma samples were 
then pipetted into labeled shipping tubes and frozen. Laboratory 
analysis was done at Burroughs Wellcome Laboratories (Research 
Triangle Park, North Carolina). 
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Concentration versus time data was plotted for each subject to 
determine peak concentration and time to peak concentration. A plot 
of the natural log concentration versus time for concentrations 
following peak concentration supplied a best fit line using Cricket 
Graph software for the Apple Macintosh computer. The slope of this 
line is the elimination rate constant k . The beta elimination 
el 
half-life (t, ) was calculated using the following equation: t, » 
-5 '5 
0,693/kel.5 
Follow-up. Follow-up assessments were performed between five 
and seven days following completion of the last dosing period. These 
included: physical examination, vital signs, body weight, 12-lead 
electrocardiogram, neurological examination, ophthalmological 
examination, CBC with differential, SMA-20, serum amylase, serum 
lipase and urinalysis, 
RESULTS 
Subjects completed only four of the five planned dosing periods 
due to the large number of adverse effects reported. The most common 
of these were nausea and vomiting following administration of the 
drug. 
Subject 5 was withdrawn from the study because his liver enzymes 
were found to be abnormally high following the second dosing period. 
A summary of his laboratory values is shown in Table 4. Subject 5' s 
physical examination and other test parameters were unchanged from 
baseline. Results of hepatitis A antibody, hepatitis B surface 
antigen, antihepatitis B surface antigen and antihepatitis B core 
antigen tests were negative for this subject. No obvious cause for 
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the elevated values was found. A determination could not be made as 
to the relationship between his laboratory abnormalities and drug 
administration. Follow-up was discontinued when the patient refused 
further evaluation. 
Subject 5 was replaced by subject 15 who was also dropped from 
the study due to a positive urinary drug screen prior to dosing 
period two. Subject 2 was dropped from the study for non-compliance 
with the protocol because his urine drug screen prior to dosing 
period four revealed ethchlorvynol metabolites. Subject 16 replaced 
this subject but withdrew for personal reasons only eight hours after 
dosing period one. 
Adverse reactions. Adverse reactions were reported by all 
subjects receiving the study medication as well as all of the sub-
jects receiving placebo. However, the number of adverse effects 
reported by subjects receiving the medication was greater than those 
reported by subjects receiving placebo. Reported adverse effects and 
their incidence are summarized in Table 6. The following adverse 
reactions were reported by one subject during one dosing period, but 
not during subsequent dosing periods: abdominal cramping, belching, 
sweating, white spots in vision, tingling tongue, numbness in right 
arm, disorientation, weakness and sedation. 
Visual Analog Scale. There was a great deal of variability in 
visual analog scale scores for most subjects. However, variations 
from baseline values which were detectable after charting of scores 
on a graph of millimeters versus time for each subject during each 
dosing period are summarized in Table 6. 
Physical Examination. Three subjects developed findings on 
physical examination which varied from their screening examinations. 
Subject 1 developed a bruise on his right shoulder following dose 
three which had resolved by pre-dose four. During the 48 hour 
examination following dose number four, subject 4 was noted to have 
white and yellow patches coating his tongue. These had resolved 
without therapy by the time of his physical examination during the 
follow-up phase of the study. Mild cervical lymphadenopathy in 
subject 12 present prior to dose four resolved by the end of the 
dosing period. 
Vital Signs. Two subjects demonstrated significant variations 
in vital signs. At eight hours following dose two, subject 3 had a 
blood pressure drop from 98/56 mmHg to 72/58 mmHg upon standing. His 
pulse rate increased from 68 to 140 beats per minute. At nine hours, 
his blood pressure was 100/72 mmHg with a pulse rate of 120 beats per 
minute. By 12 hours, no orthostatic changes were noted and values 
had returned to baseline. Subject 12 reported lightheadedness upon 
standing for vital signs before dosing and at various times during 
each dosing period, especially in the morning. His heart rate 
increased between 20 and 40 beats per minute upon standing for 
measurement of vital signs; however, the blood pressure remained 
stable during these episodes. 
Electrocardiogram. Electrocardiograms revealed only normal 
variations including sinus bradycardia, sinus tachycardia, and 
occasional atrial ectopic beats which were present at screening or 
pre-dosing for each subject in which they were noted. Twelve of the 
14 subjects from both the placebo and nonplacebo groups demonstrated 
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one or more of these normal variants which was not considered to be 
related to drug administration. 
Neurological Examination. Decreased tandem gait at two hours 
following dose three not seen on screening or pre-dose was noted in 
subject 3 (placebo). Otherwise variants were unchanged from those 
noted at screening or pre-dose. These minor variations included 
slight tremors in three subjects, decreased reflexes in two subjects 
and brisk reflexes in one subject. 
Ophtha lino logical Examination. Only one subject demonstrated 
changes between screening and follow-up ophthalmologieal examinations. 
Follow-up examination revealed corneal densities in subject 6 
(placebo group) not present at screen. Two other subjects were found 
to have abnormalities on screening which remained unchanged through-
out the study. These included mild blepharitis, early chalazion, an 
old corneal scar and anterior subscapular vacuoles in the lens in 
subject 8 and a small pigment clump on the retina of both eyes in 
subject 9. 
Laboratory Values. Other than subject 5, laboratory values for 
all subjects were judged not to be clinically significant different 
from baseline values. Several transient minor variations were noted. 
Prior to dosing period three, subject 4 (drug) had 3+ ketones in his 
urine. At 24 hours following the third dose few white blood cells 
and few red blood cells were seen on urinalysis. White blood cells 
and epithelial cells were also noted on urinalysis prior to dose 
four, but had resolved by the following day. Subject 6 (placebo) and 
Subject 8 (drug) had elevated cholesterol and serum triglycerides 
present at screen and throughout the study. Subject 7 (placebo) had 
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a slightly elevated amylase and cholesterol on screen and throughout 
the dosing periods. Subject 9 had a few white "blood cells seen on 
urinalysis following dose one and three. Subject 10 had a few white 
blood cells and epithelial cells present on urinalysis at screen and 
at dosing period four. Subject 11 had few white blood cells during 
dosing period four as well as a positive nitrite test indicating the 
presence of nitrite producing bacteria. The white blood cells were 
still present at follow-up, but the nitrite test had converted to 
negative. Urinalysis for subject 12 revealed a few white "blood cells 
at 24 hours following dose two, moderate white blood cells during the 
third dosing period, few white blood cells and moderate epithelial 
cells prior to dose four. Follow-up urinalysis was clear, Urinaly-
sis for subject 15 contained a few white blood cells prior to dose 
two and at follow-up and few red blood cells at follow-up. Urinaly-
sis revealed a few white blood cells prior to dose one and at 
follow-up. Few calcium oxalate crystals were note on urinalysis 
prior to dose one and few bacteria were seen on urinalysis at 
follow-up. 
Pharmacokinetics. The serum concentrations of BWA78U measured 
for each subject are shown in Figures I through X- Plasma samples 
were not drawn for subjects 1, 2 and 5 following administration of 
the 50 tag dose. These subjects vomited an unknown portion of their 
dose and the usefulness of samples in this situation was questioned, 
Subjects also vomited during subsequent dosing periods; however, 
plasma samples were collected and analyzed for ByA78U» 
The drug was rapidly absorbed from the gastrointestinal tract 
with a mode time to peak concentration of 0,5 hours. Time to peak 
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concentration ranged from 0.5 to 4 "hours with a mean of 1.3 hours. 
Mean peak plasma concentrations (±SD) ranged from 57 (±22) ng/r.l for 
the 25 mg dose to 244 (±133) ng/ml for the 150 mg doses. The 
elimination rate constants (k .) and elimination half-lives (t, ) are 
el % 
summarized in Table 7. Graphs for subjects 8 and 9 appeared to 
contain a bimodal peak at the higher doses. This may be due to 
delayed absorption following ernesis of part of the dose or a result 
of enterohepatic recirculation of BWA78U. In both cases, the 
elimination rate constant (k .) was calculated based on the terminal 
el 
slope of the line. Mean values for t, (±SD) for the 25 mg, 50 mg, 
100 mg and 150 mg doses are 1.56 (±0.86), 1.53 (+0.34), 1.16 (±0,29) 
and 1.53 (±0.36) hours respectively. Preliminary animal data 
supplied by Burroughs Wellcome Gompany indicated that the half-life 
of BWA78U is dose dependant. In this study, the half-life did not 
increase with increasing doses. This may be explained in one of 
several ways: 1) elimination in humans is not dose dependant 2) 
eraesis of the larger doses made only part of the administered drug 
available to systemic circulation and subjects did not actually 
absorb increased doses of BWA78U 3) the relative dose of BWA78U 
given to humans was less than that given to the experimental animals 
and doses were not high enough to saturate enzymes responsible for 
metabolism. 
DISCUSSION 
The use of many antiepileptic agents is limited by their adverse 
effects. Animal studies indiced that BWA78U exhibited minor adverse 
effects only at doses greater than antiepileptic doses and may offer 
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an advantage In decreased toxicity. The projected antiepileptic dose 
in humans is 0.5 to 1 mg/kg; however, many subjects experienced 
nausea, vomiting and dizziness during the first and second dosing 
periods when given 25 mg and 50 mg BWA78U. Peak plasma levels of 
BWA78U achieved in rats given doses adequate to control experimen-
tally induced seizures ranged from 180 to 660 ng/ml.2 This is higher 
than mean peak plasma concentrations achieved by subjects in this 
study which ranged from 57 to 244 ng/ml. Although direct extrapola-
tion of serum concentration data from animals to humans is 
impossible, the above indicates that doses of drug within the range 
needed to control seizures in humans are unlikely to be tolerated. 
The nausea, vomiting and dizziness are not considered life 
threatening. However, when experienced by patients taking a 
medication requiring long-term treatment, they render the treatment 
intolerable. 
Subjects were encouraged not to discuss adverse effects with 
each other. However, all subjects were housed in the Drug Research 
Center during each dosing period and some observation and communica-
tion of other's adverse effects were inevitable. This "group effect" 
may have caused some subjects to be more acutely aware of adverse 
effects of the medication. However, both subjects and investigators 
were blinded as to which subjects received drug and which subjects 
received placebo. A significantly larger proportion of adverse 
effects were reported by subjects receiving drug than by subjects 
receiving placebo. For example, nausea was reported in 21 of 31 drug 
administrations while it was reported only once following 16 doses of 
placebo. Large differences between drug and placebo groups were also 
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evident in the number of reports of vomiting and dizziness. Differ-
ences in numbers of reported instances of headache, lethargy, 
trembling, chills and increased salivation were much smaller and in 
the case of increased salivation reported in only one subject receiv-
ing placebo. The differences between groups in number of adverse 
effects reported could indicate that drug administration did cause 
nausea, vomiting and dizziness in a significant portion of subjects. 
Although some subjects reported adverse central nervous system 
effects such as dizziness and drowsiness, many more of these became 
6 
evident on completion of the visual analog scale. Nicholson 
cautions that the visual analog scale measures subjective effects and 
points to several examples where visual analog scale measurements 
were much less sensitive than performance testing in assessing drug 
effects. He also summarizes two studies in which visual analog 
scales were unable to distinguish between effects which were evident 
on performance measurements in patients taking different doses of 
central nervous system depressants. However, the goal of this study 
was to act as a gross screening measure for adverse effects of 
BWA78U, For this purpose, the visual analog scale offered many 
advantages. It was easy to explain, could be filled out and scored 
quickly, required no elaborate equipment and little motivation on the 
part of the subjects filling out the form.7 Due to the small patient 
population and the small number of subjects completing all dosing 
periods, statistical analysis on the scores was not done. However, 
visual inspection of the graphed scores did point out some areas 
which subjects consistently rated higher during hour one and two 
visual analog scales. These included ratings of drowsiness, 
14 
sluggishness, confusion and feeling mentally slow at times when serum 
concentrations of the parent compound were at their peak. Further 
studies with this medication should focus on the adverse central 
nervous system effects. 
No changes which were likely attributable to the drug were found 
in neurological, ophthalmological, physical examinations, electro-
cardiograms or vital signs. These results agree with those from 
animal studies. Few effects other than emesis and diarrhea were seen 
at low doses in dogs. Moderate doses not reached by subjects in this 
trial lead to ataxia and tremor. Animal studies did demonstrate 
spontaneous retinal atrophy in placebo and experimental groups. As 
this effect was more pronounced with higher doses in animals, this is 
an effect which may become evident with higher doses or with chronic 
dosing studies in humans. 
SUMMARY 
Trials of BWA78U in animals indicated that this may be an effec-
tive antiepileptic medication with an acceptable margin of safety and 
tolerance. The purpose of this study was to assess tolerance of 
escalating doses of BWA78U in human volunteers. Reports of adverse 
effects included nausea, vomiting and dizziness which were likely due 
to the drug. Because of the large number of reported adverse effects 
during the first dosing periods, subjects received only four of the 
five planned drug administrations. One subject also developed 
increases in serum transaminases. The relationship of these in-
creases to drug administration could not be determined. The low 





NUMBER OF SUBJECTS RECEIVING BWA7SU OR PLACEBO IN EACH GROUP 
Treatment 
Group BWA78U Placebo Total 
1 4 2 6 
II 4 2 6 





Group 1 2 3 4 5 6 
25 mg 50 mg 100 mg 150 mg 300 mg 
dose dose dose dose dose 
II 25 mg 50 mg 100 mg 150 mg 300 mg 
dose dose dose dose dose 
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TABLE 3 
TREATMENT PHASE ASSESSMENTS 
Hours After Drug Administration 
Measurement Pre-
Dose 
0.5 1.0 1.5 2 3 4 6 8 10 12 24 36 48 
Physical Exam X X 
Vital Signs X X X X X X X X X X 
EGG1 X X X 
2 
Neuro Exam X X X 
3 
ADR Probe X X X X X X X X X 
4 
VAS X X X X X X X X 
BWA78U X X X X X X X X X X X X X X 
plasma sample 
EGG = 12-lead electrocardigram 
Neuro Exam = neurological examination 
ADR Probe = probe for adverse drug reaction 
VAS = visual analog scale administration 
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TABLE 4 
LABORATORY VALUES FOR SUBJECT 5 
Date 
LAB Pre- 5/18 5/20 5/21 5/22 5/23 5/24 5/28 5/31 6/03 
(normal dose 
range) 
LDH 145 254 365 393 336 246 213 152 167 207 
(133-333 
IU/L) 
AST 40 133 338 320 348 266 177 65 123 143 
(9-55 IU/L) 




REPORTED ADVERSE EFFECTS 
Effect 25 mg 50 mg 100 mg 150 mg 
drug placebo drug placebo drug placebo drug placebo 
(10) (4) (8) (4) (7) (4) (6) (4) 
Nausea 3 7 6 1 5 
Vomiting 3 4 - 3 
Dizziness 2 1 5 1 4 - 4 
Headache 1 - 1 1 1 - 1 
Lethargy 1 - 1 
Trembling - 1 - 1 - 1 
Chills - - 1 
Increased 1 1 -
salivation 
( ) indicates number of subjects receiving each dose 




VISUAL ANALOGUE SCALE SCORE SUMMARY 
Subject # Dosing 
period 
* 












drowsy, sluggish, incompetent 
drowsy, sluggish, discontent, sad, bored 








drowsy, weak, sluggish 1,2 





















3,4 drowsy, weak, confused, clumsy, 





2 j 3 j ^  drowsy, weak, confused, clumsy, 










drowsy, sluggish 1,2 
scores highly variable, no pattern noted -
Subject 12 
(drug) 







a dash (-) Indicates that scores for this dosing period were fairly 
consistent and no discernable -variations from baseline were evident 
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TABLE 7 
SUMMARY OF HALF-LIVES AND ELIMINATION RATE CONSTANTS 
FOR BWA78U IN HUMAN VOLUNTEERS 






















#1 0.352 1.97 ND ND 0.862* 0.80* 0.369* 
* 
1.88 
#2 0.213 3.25 ND ND 0,580* 
* 
1.20 - _ 
#4 0.645 1.07 0.559 1.24 0.472 1.47 0.437 1.59 
#5 1.017 0.69 ND ND - - - -
#8 1.073 0.65 0.603 1.15 0.539 1.29 0.625 1.11 










#12 0.631 1.10 0.380 1.82 0.854 0.81 0.650 1.07 
#15 0.265 2.62 -
-
- - - -
#16 0.575 1.21 - - - - - -
Mean 0.573 1.56 0.472 1.53 0.635 1.16 0.478 1.53 
+ SD 0.293 0.86 0.107 0.34 0.168 0.29 0.129 0.36 
ND indicates blood not drawn due to eir.esis of dose 
* 
indicates ernesis of undetermined amount of dose 

























CONCENTRATION VERSUS TIME DATA FOR SUBJECT #1 
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CONCENTRATION VERSUS TIME DATE FOR SUBJECT #4 
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-0- 25 mg 
time (hours) 
FIGURE IV 












































CONCENTRATION VERSUS TIME DATA FOR SUBJECT #11 
500 
-a- 25 mg 
50 mg 
100 mg 
-o- 150 mg 
time (hours) 
FIGURE VIII 

















CONCENTRATION VERSUS TIME DATA FOR SUBJECT #16 
APPENDICES 
APPENDIX I 
CONSENT OF PARTICIPATE IN A RESEARCH STUDY 
Acute Dose Tolerance and Pharmacokinetic Study of 
BWA78U and Placebo in Normal Volunteers 
You are being invited to participate in a research project that will 
evaluate up to five different doses of a new experimental drug called 
BWA78U (made by Burroughs Wellcome Co.) in normal male volunteers. 
This study will compare the safety of this experimental drug to a 
placebo (sugar pill) . This new drug has been shown to have anti-
seizure properties in animals. 
PROCEDURES 
This study will be conducted in the University of Utah's Drug 
Research Center over a period of 7 weeks. Each volunteer will be 
randomly assigned to receive the active drug or a placebo throughout 
the study. Each volunteer will undergo a screening history and 
physical examination and a neurological examination (primarily 
consisting of testing your balance and reflexes) between 1 and 3 
weeks prior to entering the study. This will also include an eye 
exam, an electrocardiogram [ECG] (painless electrical tracing of your 
heart), answering questions on how you feel, getting blood drawn from 
your vein for laboratory tests (4 teaspoonsful) and a urinalysis. If 
you are found to be healthy, you will be asked to continue the study. 
This will involve staying in the Drug Research Center for 48 hours on 
5 different occasions, separated by one week intervals. During the 
dosing periods you will receive either a placebo every time or the 
drug BWA78U. Neither you nor any of the investigators will know 
whether you are receiving drug or placebo. This information is 
available, however, in case it is needed. 
You will receive a single dose of the drug or placebo as an oral 
capsule each dosing period. The dose will start at 25 mg and in-
crease to 50 mg, 100 mg, 150 mg and finally 300 mg. You must not 
take any alcohol, nonprescription or prescription medications from 4 
days prior to the first dosing period until the end of the entire 
study. You should also refrain from eating or drinking anything that 
contains caffeine for 24 hours prior to taking each dose of the drug. 
During each of the dosing periods, your heart rate and blood pressure 
will be recorded before you take the drug and at 1/2,1,1.5,2,3,8,10, 
12,24,36 and 48 hours after you take the drug. You will have an ECG 
done prior to receiving the drug, 2 and 48 hours after receiving the 
drug. You will be asked how you feel and to complete a questionnaire 
prior to receiving the drug and 1,2,4,8,12,24,36 and 48 hours after 
receiving the drug. You will have a neurological exam 2 and 48 hours 
after receiving the drug. We will draw blood from your vein for 
routine laboratory tests and also to measure drug levels. Blood will 
be drawn one hour prior to receiving the drug, at drug administra-
tion, 1/2, 1, 1.5, 2,3,4,6,8,10,12,24,36 and 48 hours after the drug. 
This will be a total of approximately 4.5 ounces of blood over the 48 
hour dosing period. We will also collect all of your urine during 
the 48 hours. The same procedure will be followed for each of the 5 
dosing periods. Five to 7 days after the last dosing period, you 
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will return for a follow-up visit. This will include a physical 
examination, neurological examination, electrocardiogram, eye exami-
nation and blood drawn for routine laboratory tests. Over the 7 
weeks we will remove approximately 25 ounces of blood. 
DISCOMFORTS AND RISKS 
This drug may cause an allergic reaction if you have a known hyper-
sensitivity to other similar drugs, such as theophylline. The side 
effects that you might experience are sedation, tremor, dizziness, 
fatigue, excessive salivation, nausea and diarrhea. 
There is some discomfort associated with getting your blood drawn. 
You may also get a bruise at the site of the needle insertion. 
BENEFITS 
There is no direct benefit to you for your participation in this 
study. You will receive payment for the inconvenience of being 
hospitalized ($200 per dosing period completed). 
CONFIDENTIALITY 
Your medical records will be kept confidential and you will not be 
identified in any personal way in publications on the study results. 
However, your medical records may be inspected by the sponsor 
(Burroughs Wellcome Co.), or the FDA (Food and Drug Administration) 
to assess compliance with the study protocol. 
If you have any questions about this study at any time, you should 
contact Dr. Jean Nappi at 582-1565 beeper #293 (24 hours/day) or Dr. 
Keith Tolman at 581-7802. If you have a question or problem that 
cannot be discussed with the investigators, you may call the IRB 
(Institutional Review Board) office at 581-3655. 
Your participation in this study is completely voluntary and you may 
withdraw at any time. If you choose to withdraw, it will not 
influence the medical care that you receive in any way, 
MEDICAL TREATMENT OR COMPENSATION FOR PHYSICAL INJURY 
In the event you sustain physical injury from the research project in 
which you are participating, the University of Utah will provide you, 
without charge, emergency and temporary medical treatment not other-
wise covered by insurance. Furthermore, if your injuries are caused 
by negligent acts or omissions of University employees acting in the 
course and scope of their employment, the University may be liable, 
subject to limitations prescribed by law, for additional medical 
costs and other damages you sustain. If you believe you have 
suffered physical injury as result of participation in this research 
program, please contact the Office of Research Administration, 
telephone number 581-6903. 




Volunteers must meet the following criteria at the time of screening: 
a) Be males between the ag es of 18 and 55 years. 
b) Weigh within 15% of the ideal weight for their height and 
body frame. 
c) Have not taken any alcoholic beverages or over the counter 
medication from 96 hours prior to Dosing Period 1 until 
completion of follow-up assessments. 
d) Have not taken any caffeine-containing products (including 
chocolate) for 24 hours prior to entering each Dosing 
Period. 
e) Have not taken any prescription medication from one week 
prior to Dosing Period 1 or psychoactive substances from 
two weeks prior to Dosing Period 1 until completion of 
follow-up assessments. 
f) Not have a a history of hypersensitivity to drugs either 
chemically (i.e., purines) or pharmacologically (i.e. 
xanthines or methylxanthines) related to BWA78U. 
g) Have no clinically significant history of: a disorder of 
the cardiovascular, respiratory, neurological, endocrine, 
liver (including hepatitis B) , genitourinary, ophthalmo-
logical, gastrointestinal, or reticuloendothelial system; 
or psychiatric disorder requiring hospitalization; or other 
chronic diseases. 
h) Not have any condition which may affect the absorption, 
distribution, metabolism or excretion of drugs. 
38 
APPENDIX III 
VISUAL ANALOG SCALE 
INSTRUCTIONS: 
1. Please rate the way you feel at this moment in terms of the 
dimensions given below. 
2. Regard the line as representing the full range of each dimension. 
3. Rate your feelings as they are at the moment. 
4. Mark clearly and perpendicularly across each line. 
ALERT DROWSY 
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